Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · IEX Real-Time Price · USD
128.77
+1.38 (1.08%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Sarepta Therapeutics Employees
Sarepta Therapeutics had 1,314 employees on December 31, 2023. The number of employees increased by 152 or 13.08% compared to the previous year.
Employees
1,314
Change (1Y)
152
Growth (1Y)
13.08%
Revenue / Employee
$946,222
Profits / Employee
-$407,897
Market Cap
12.17B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,314 | 152 | 13.08% |
Dec 31, 2022 | 1,162 | 322 | 38.33% |
Dec 31, 2021 | 840 | -26 | -3.00% |
Dec 31, 2020 | 866 | 123 | 16.55% |
Dec 31, 2019 | 743 | 244 | 48.90% |
Dec 31, 2018 | 499 | 244 | 95.69% |
Dec 31, 2017 | 255 | 58 | 29.44% |
Dec 31, 2016 | 197 | -73 | -27.04% |
Dec 31, 2015 | 270 | 66 | 32.35% |
Dec 31, 2014 | 204 | 58 | 39.73% |
Dec 31, 2013 | 146 | 43 | 41.75% |
Dec 31, 2012 | 103 | 5 | 5.10% |
Dec 31, 2011 | 98 | 0 | - |
Dec 31, 2010 | 98 | 35 | 55.56% |
Dec 31, 2009 | 63 | -20 | -24.10% |
Dec 31, 2008 | 83 | -42 | -33.60% |
Dec 31, 2007 | 125 | 8 | 6.84% |
Dec 31, 2006 | 117 | -6 | -4.88% |
Dec 31, 2005 | 123 | 11 | 9.82% |
Dec 31, 2004 | 112 | 6 | 5.66% |
Dec 31, 2003 | 106 | 17 | 19.10% |
Dec 31, 2002 | 89 | 4 | 4.71% |
Dec 31, 2001 | 85 | 14 | 19.72% |
Dec 31, 2000 | 71 | 15 | 26.79% |
Dec 31, 1999 | 56 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fresenius Medical Care AG & Co. KGaA | 119,845 |
DaVita | 70,000 |
Dr. Reddy's Laboratories | 25,863 |
Charles River Laboratories International | 21,800 |
Medpace Holdings | 5,900 |
Insulet | 3,000 |
Incyte | 2,524 |
ShockWave Medical | 1,468 |
SRPT News
- 3 days ago - Sarepta Therapeutics to Announce First Quarter 2024 Financial Results - Business Wire
- 21 days ago - Outperforming ETF manager names a potential ‘50-bagger' in the stock market - Market Watch
- 4 weeks ago - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Sarepta Therapeutics to Present at Upcoming Investor Conferences - Business Wire
- 2 months ago - Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program - Business Wire
- 2 months ago - Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments - Business Wire
- 2 months ago - Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results - Business Wire
- 2 months ago - U.S. FDA to not conduct advisers' meet for Sarepta's Duchenne gene therapy - Reuters